NCT01358877 2025-11-28
APHINITY
Hoffmann-La Roche
Phase 3 Completed
Clinical Trials
70 trialsNCT03036488 2025-10-29
MK-3475-522
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03013504 2024-11-06
TROIKA
Prestige Biopharma Limited
Phase 3 Completed
NCT00630032 2024-02-21
TavIx
UNICANCER
Phase 3 Completed
NCT00129935 2023-03-31
EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT00129922 2023-03-06
Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT01726452 2022-09-30
NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)
Cancer Trials Ireland
Phase 3 Completed
NCT00087178 2022-08-11
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
NSABP Foundation Inc
Phase 3 Completed
NCT01966471 2022-06-14
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT03556358 2022-01-14
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With HerceptinĀ® in HER2+ Early Breast Cancer
Tanvex BioPharma USA, Inc.
Phase 3 Completed
NCT02395640 2021-10-26
The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
Fudan University
Phase 3 Completed
NCT00003606 2021-02-21
Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
UNICANCER
Phase 3 Completed
NCT02324088 2021-02-21
PEGASE07
UNICANCER
Phase 3 Completed
NCT01690702 2021-02-02
GAIN-2
GBG Forschungs GmbH
Phase 3 Completed
NCT00309569 2020-10-14
Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients
Austrian Breast & Colorectal Cancer Study Group
Phase 3 Completed
NCT00014222 2020-10-05
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT01026116 2020-05-12
A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old
Fudan University
Phase 3 Completed
NCT00052910 2020-05-07
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT04031703 2020-04-24
Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)
Fudan University
Phase 3 Completed
NCT00002542 2020-04-01
Tamoxifen in Treating Women With High-Risk Breast Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT04127019 2020-02-26
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
Fudan University
Phase 3 Completed
NCT02115204 2019-10-03
4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
West German Study Group
Phase 3 Completed
NCT01049425 2019-08-14
planB
West German Study Group
Phase 3 Completed
NCT02042690 2019-05-29
Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients
Peking University
Phase 3 Completed
NCT00776724 2019-05-06
TaiNAC
National Taiwan University Hospital
Phase 3 Completed
NCT03888677 2019-03-28
Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer
Uppsala University Hospital
Phase 3 Completed
NCT00513292 2019-01-23
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00689156 2018-04-05
READ
Danish Breast Cancer Cooperative Group
Phase 3 Completed
NCT00950300 2018-01-23
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT02980965 2017-11-13
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
Fudan University
Phase 3 Completed
NCT02001506 2017-08-29
Neo-shorter
Asan Medical Center
Phase 3 Completed
NCT02125344 2017-07-13
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
GBG Forschungs GmbH
Phase 3 Completed
NCT00544232 2016-02-15
Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)
GBG Forschungs GmbH
Phase 3 Completed
NCT00540800 2016-01-14
BREAST-10
National Cancer Institute, Naples
Phase 3 Completed
NCT01433614 2015-09-17
TEX
Karolinska University Hospital
Phase 3 Completed
NCT02450058 2015-05-21
MIG5
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Phase 3 Completed
NCT00424606 2015-05-20
Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients
Hellenic Oncology Research Group
Phase 3 Completed
NCT00718354 2015-05-13
GASTRANOX
Thrombosis Research Institute
Phase 3 Completed
NCT00615602 2015-03-04
Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
Hellenic Oncology Research Group
Phase 3 Completed
NCT00658580 2015-02-12
Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer
European Lung Cancer Working Party
Phase 3 Completed
NCT00002870 2014-12-16
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer
UNICANCER
Phase 3 Completed
NCT00196872 2014-07-17
A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)
GBG Forschungs GmbH
Phase 3 Completed
NCT01985724 2014-05-14
Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer
Hellenic Oncology Research Group
Phase 3 Completed
NCT01053390 2013-12-20
New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 3 Completed
NCT00002615 2013-12-19
Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003577 2013-12-19
Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003893 2013-12-19
Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00002898 2013-12-04
Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00002953 2013-12-04
Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003012 2013-11-06
Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed